Royalty Pharma Plc

( )
RPRX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson -3.27%138.470.7%$830.15m
PFEPfizer Inc. -5.30%35.450.9%$789.81m
MRKMerck & Co., Inc. -2.31%76.190.7%$626.60m
BMYBristol-Myers Squibb Co. -1.65%57.771.0%$567.37m
ABBVAbbVie, Inc. -2.68%80.491.9%$557.75m
LLYEli Lilly & Co. -0.48%131.271.1%$494.66m
AZNAstraZeneca Plc -2.86%50.981.2%$206.87m
GSKGlaxoSmithKline Plc -3.93%33.960.2%$147.19m
NVSNovartis AG -3.25%78.320.2%$140.00m
NVONovo Nordisk A/S -2.06%66.550.1%$67.40m
RGENRepligen Corp. -2.64%171.207.1%$64.29m
RPRXRoyalty Pharma Plc -4.62%36.120.2%$59.77m
TPTXTurning Point Therapeutics, Inc. 4.34%104.420.0%$56.83m
AMAGAMAG Pharmaceuticals, Inc. 0.07%13.7122.1%$46.96m
SNYSanofi -2.66%46.140.2%$46.38m

Company Profile

Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.